[미국특허]
Di-steroidal prodrugs of ethinyl estradiol
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A01N-031/56
C07J-009/00
C07C-049/00
C07C-049/423
출원번호
US-0009617
(2004-12-10)
발명자
/ 주소
King,John Alexander
Keown,James
McIlroy,James William
Armstrong,William Paul
McKervey,Michael Anthony
McMordie,Austin
출원인 / 주소
Warner Chilcott Company, Inc.
대리인 / 주소
Fitzpatrick, Cella, Harper &
인용정보
피인용 횟수 :
3인용 특허 :
14
초록
The present invention is a di-steroidal prodrug of ethinyl estradiol according to formula I:
대표청구항▼
What is claimed is: 1. A di-steroidal prodrug of ethinyl estradiol having the following formula: wherein R is selected from the group consisting of wherein X and Y are independently selected from and Z is (i) an aliphatic straight chain having 1 to 10 carbon atoms which may be saturated or
What is claimed is: 1. A di-steroidal prodrug of ethinyl estradiol having the following formula: wherein R is selected from the group consisting of wherein X and Y are independently selected from and Z is (i) an aliphatic straight chain having 1 to 10 carbon atoms which may be saturated or unsaturated and optionally may be substituted by one or more lower alkyl, hydroxy or amino groups, (ii) description="In-line Formulae" end="lead"A--B--Ddescription="In-line Formulae" end="tail" wherein A and D are independently --CO(CH2)f--, wherein f is 0 to 5, and B is--O--(CH2CH2O)p--, wherein p is 1 to 700, or (iii) a peptide linkage having 2 to 15 amino acid units derived independently from amino acids selected from the group consisting of alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, or combinations thereof wherein the end groups of the peptide are amino acid units independently derived from aspartic acid and glutamic acid. 2. The prodrug of claim 1, wherein R is 3. The prodrug of claim 1, wherein R is selected from the group consisting of: 4. The prodrug of claim 1, wherein R is 5. The prodrug of claim 1, wherein said prodrug is selected from the group consisting of di-(3-ethinyl estradiol) carbonate, di-(3-ethinyl estradiol) malate, di-(3-ethinyl estradiol) succinate, di-(3-ethinyl estradiol) glutarate, di-(3-ethinyl estradiol) adipate, di-(3-ethinyl estradiol) fumarate, di-(3-ethinyl estradiol) glutamate, di-(3-ethinyl estradiol) aspartate, and pharmaceutically acceptable salts thereof. 6. A pharmaceutical dosage unit comprising: (a) a di-steroidal prodrug of ethinyl estradiol having the following formula: wherein R is selected from the group consisting of wherein X and Y are independently selected from and Z is (i) an aliphatic straight chain having 1 to 10 carbon atoms which may be saturated or unsaturated and optionally may be substituted by one or more lower alkyl, hydroxy or amino groups, (ii) description="In-line Formulae" end="lead"A--B--Ddescription="In-line Formulae" end="tail" wherein A and D are independently --CO(CH2)f--, wherein f is 0 to 5, and B is--O--(CH2CH2O)p--, wherein p is 1 to 700, or (iii) a peptide linkage having 2 to 15 amino acid units derived independently from amino acids selected from the group consisting of alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, or combinations thereof wherein the end groups of the peptide are amino acid units independently derived from aspartic acid and glutamic acid; and (b) one or more pharmaceutically acceptable excipients. 7. A method of synthesizing a di-steroidal prodrug of ethinyl estradiol having the formula wherein R is selected from the group consisting of wherein X and Y are independently selected from and Z is (i) an aliphatic straight chain having 1 to 10 carbon atoms which may be saturated or unsaturated and optionally may be substituted by one or more lower alkyl, hydroxy or amino groups, (ii) description="In-line Formulae" end="lead"A--B--Ddescription="In-line Formulae" end="tail" wherein A and D are independently --CO(CH2)f--, wherein f is 0 to 5, and B is--O--(CH2CH2O)p--, wherein p is 1 to 700, or (iii) a peptide linkage having 2 to 15 amino acid units derived independently from amino acids selected from the group consisting of alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, or combinations thereof wherein the end groups of the peptide are amino acid units independently derived from aspartic acid and glutamic acid, comprising the steps of: (A) providing ethinyl estradiol or a derivative thereof; (B) admixing said ethinyl estradiol and a linking agent, wherein said linking agent is selected from the group consisting of: (a) a carbonate; (b) an aliphatic diacid having a backbone of 1 to 10 carbon atoms; description="In-line Formulae" end="lead"(c) G--CO--Z--X--Gdescription="In-line Formulae" end="tail" wherein G is a halogen; (d) a peptide linkage having 2 to 15 amino acid units derived independently from amino acids selected from the group consisting of alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, or combinations thereof wherein the end groups of the peptide are amino acid units independently derived from aspartic acid and glutamic acid; (e) a tert-butoxycarbonyl protected cysteic acid; and (f) a polyethylene glycol and succinic anhydride, (C) optionally, admixing a coupling agent and/or a base, thereby forming said di-steroidal prodrug of ethinyl estradiol or pharmaceutically acceptable salt thereof. 8. The method of claim 7, wherein said linking agent is a carbonate, description="In-line Formulae" end="lead"H--Y--Z--X--H, ordescription="In-line Formulae" end="tail" description="In-line Formulae" end="lead"G--CO--Z--X--Gdescription="In-line Formulae" end="tail" wherein G is a halogen. 9. The method of claim 7, wherein said coupling agent is selected from the group consisting of: bis(4-nitrophenyl)carbonate, 1-(3-dimethylaminopropyl)-3-ethyl-carbodiimide hydrochloride, and mixtures thereof. 10. The method of claim 7, wherein said at least one base is selected from the group consisting of: 4-dimethylamino pyridine, triethylamine, and mixtures thereof. 11. The method of claim 7, wherein said prodrug is di-(3-ethinyl estradiol) carbonate or a pharmaceutically acceptable salt thereof. 12. The method of claim 7, wherein said prodrug is selected from the group consisting of: di-(3-ethinyl estradiol) succinate, di-(3-ethinyl estradiol) malate, di-(3-ethinyl estradiol) glutarate, di-(3-ethinyl estradiol) adipate, di-(3-ethinyl estradiol) fumarate, di-(3-ethinyl estradiol) glutamate, di-(3-ethinyl estradiol) aspartate, and a pharmaceutically acceptable salt thereof. 13. A method of providing contraception comprising the step of: administering to a patient in need thereof, an effective amount of said di-steroidal prodrug of ethinyl estradiol of claim 1, for an effective period of time. 14. A method of providing hormone treatment therapy to a patient in need thereof, comprising the step of: administering to said patient in need thereof, an effective amount of said di-steroidal prodrug of ethinyl estradiol of claim 1, for an effective period of time.
Gouin Sebastien,CAX ; Zhu Xiao-Xia,CAX, Biodegradable polanhydrides derived from dimers of bile acids, and use thereof as controlled drug release systems.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.